{"id":"https://openalex.org/W4244664894","doi":"https://doi.org/10.1128/aac.00270-08","title":"The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral","display_name":"The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral","publication_year":2008,"publication_date":"2008-04-24","ids":{"openalex":"https://openalex.org/W4244664894","doi":"https://doi.org/10.1128/aac.00270-08"},"language":"en","primary_location":{"id":"doi:10.1128/aac.00270-08","doi":"https://doi.org/10.1128/aac.00270-08","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.00270-08","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2346662","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110166075","display_name":"Edward P. Garvey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Edward P. Garvey","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048833977","display_name":"Brian A. Johns","orcid":"https://orcid.org/0000-0001-5526-3682","observed_orcids":["https://orcid.org/0000-0001-5526-3682"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Brian A. Johns","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083690472","display_name":"Margaret J. Gartland","orcid":"https://orcid.org/0000-0002-1200-3706","observed_orcids":["https://orcid.org/0000-0002-1200-3706"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Margaret J. Gartland","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015151871","display_name":"Scott A. Foster","orcid":"https://orcid.org/0000-0002-2773-7999","observed_orcids":["https://orcid.org/0000-0002-2773-7999"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Scott A. Foster","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078619546","display_name":"Wayne H. Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Wayne H. Miller","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010566547","display_name":"Robert G. Ferris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Robert G. Ferris","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056112208","display_name":"Richard J. Hazen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Richard J. Hazen","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056086220","display_name":"Mark Underwood","orcid":"https://orcid.org/0000-0002-6803-2346","observed_orcids":["https://orcid.org/0000-0002-6803-2346"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mark R. Underwood","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072238598","display_name":"Eric E. Boros","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Eric E. Boros","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004213379","display_name":"James B. Thompson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"James B. Thompson","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023401822","display_name":"Jason G. Weatherhead","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Jason G. Weatherhead","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029024531","display_name":"Cecilia S. Koble","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Cecilia S. Koble","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051471000","display_name":"Scott H. Allen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Scott H. Allen","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076705601","display_name":"Lee T. Schaller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Lee T. Schaller","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050244179","display_name":"Ronald G. Sherrill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ronald G. Sherrill","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069012570","display_name":"Tomokazu Yoshinaga","orcid":"https://orcid.org/0000-0001-5578-2212","observed_orcids":["https://orcid.org/0000-0001-5578-2212"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomokazu Yoshinaga","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102978015","display_name":"Masanori Kobayashi","orcid":"https://orcid.org/0000-0002-9067-859X","observed_orcids":["https://orcid.org/0000-0002-9067-859X"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masanori Kobayashi","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008379236","display_name":"Chiaki Wakasa-Morimoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Chiaki Wakasa-Morimoto","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038814610","display_name":"Shigeru Miki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shigeru Miki","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071339903","display_name":"Koichiro Nakahara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Koichiro Nakahara","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018757118","display_name":"Takeshi Noshi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takeshi Noshi","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041689745","display_name":"Akihiko Sato","orcid":"https://orcid.org/0000-0001-6625-1679","observed_orcids":["https://orcid.org/0000-0001-6625-1679","https://orcid.org/0009-0008-0753-4394"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akihiko Sato","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110083853","display_name":"Tamio Fujiwara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]},{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tamio Fujiwara","raw_affiliation_strings":["Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Virology and Medicinal Chemistry, Infectious Diseases Center of Excellence for Drug Discovery, and Department of Discovery Technology Group, Molecular Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, and Shionogi Research Laboratories, Shionogi and Company, Ltd., Mishima, Settsu-shi, Osaka 556-0022, Japan","institution_ids":["https://openalex.org/I4210115149","https://openalex.org/I4210118477"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.49126876,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"52","issue":"5","first_page":"1899","last_page":"1899"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/naphthyridinones","display_name":"naphthyridinones","score":0.9760000109672546},{"id":"https://openalex.org/keywords/hiv-1-integrase-inhibitors","display_name":"HIV-1 integrase inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/antiretroviral-drugs","display_name":"antiretroviral drugs","score":0.8980000019073486},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.7089999914169312},{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C14430832","wikidata":"https://www.wikidata.org/wiki/Q412550","display_name":"Integrase","level":3,"score":0.7941111326217651},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.7526546120643616},{"id":"https://openalex.org/C2777302000","wikidata":"https://www.wikidata.org/wiki/Q412251","display_name":"Integrase inhibitor","level":5,"score":0.7199540734291077},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5365398526191711},{"id":"https://openalex.org/C2779690655","wikidata":"https://www.wikidata.org/wiki/Q374232","display_name":"Lentivirus","level":4,"score":0.533416211605072},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4035670757293701},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34920021891593933},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.3370784521102905},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.23577794432640076},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.14235535264015198}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1128/aac.00270-08","doi":"https://doi.org/10.1128/aac.00270-08","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.00270-08","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2346662","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2346662","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2346662","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2346662","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8371999859809875,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2549369549","https://openalex.org/W2073031487","https://openalex.org/W1997341087","https://openalex.org/W2060921417","https://openalex.org/W1983091740","https://openalex.org/W2030484172","https://openalex.org/W7099214531","https://openalex.org/W2092425328","https://openalex.org/W1985113015","https://openalex.org/W32389250"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-05-12T00:00:00"}